The Kraft Group-backed spinal muscular atrophy drug developer has raised more than $100m in funding since 2012.

Scholar Rock, the US-based spinal muscular atrophy (SMA) therapy developer backed by conglomerate Kraft Group, has filed to raise up to $75m in an initial public offering.

Founded in 2012, Scholar Rock is working on monoclonal antibodies that will treat diseases associated with signalling by protein growth factors, by targeting the proteins at a cellular level.

The IPO proceeds will advance the company’s lead drug candidate, an SMA treatment called SRK-015, into phase 1 clinical trials later this year.

…